Loading...
Molecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?
Darling, John L.
Darling, John L.
Authors
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2006
Submitted date
Files
Alternative
In: The 33rd Congress of the Czech Society of Pathologists, 2nd Satellite Symposium & Workshop on Molecular Pathology, Regional Centre Olomouc & Faculty of Medicine, Palacky University Olomouc, May 4–6, 2006, 20-22
Abstract
Although in comparison to breast, lung and colon cancer, the brain is a relatively uncommon site for the development of cancer, the brain is the tenth most common site for the development of cancer in men and about the twelfth in women. This translates to about 6,000 individuals in the UK developing a primary malignant brain tumour every year. Cancer of the brain develops in two distinct age groups, although the types of tumour that develop in these two age groups differ markedly. There is a peak of incidence in the first decade of life, and brain tumours rank with leukaemia as a leading cause of cancer death in children. These tumours tend to be indolent low-grade astrocytomas or highly malignant primitive neuroectodermal tumours like medulloblastoma. However, the vast majority of brain tumours occur with increasing frequency in the sixth, seventh and eight decade of life and they are the second fastest growing cause of cancer death among those over 65. These tumours tend to be malignant astrocytomas particularly the most malignant variety, glioblastoma multiforme (GBM). Unlike lung cancer or malignant melanoma there is no strong evidence of an environmental carcinogen associated with the development of these tumours and no change in behaviour reduces risk.
Citation
Biomedical Papers, 150(Suppl 1): 20-22
Journal
Research Unit
DOI
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Conference contribution
Language
en
Description
The author is extremely grateful for the financial support by the Brain Research Trust, Samantha Dickson Research Trust, Brain Tumour UK, the Colin Oliphant Trust and the University of Wolverhampton. Abstract is provided here courtesy of Palacky University, Olomouc.
Series/Report no.
ISSN
1213-8118